KORU Medical Systems, Inc. announced that following five years of service to the Company, Linda Tharby, President, will retire effective June 30, 2026. The Board of Directors has appointed Adam Kalbermatten, currently Chief Commercial Officer, as President, effective March 15, 2026. The result of thoughtful, long-range succession planning, this transition reflects the Board?s confidence in Mr. Kalbermatten?s experience and capabilities, the Company?s strategic direction, and the depth of KORU?s leadership team.
Ms. Tharby will remain on the Board of Directors and serve in an advisory capacity through the end of 2026 to support this leadership succession plan. Under Ms. Tharby?s leadership, KORU Medical underwent significant transformation, doubling its recurring patient base to over 55,000 patients, expanding its international footprint, and broadening the Freedom infusion platform beyond immunoglobulin to new drug classes. During her tenure, the Company delivered consistent revenue growth, achieved profitability, and established KORU Medical as a recognized market leader.
Mr. Kalbermatten joined KORU Medical in 2025 as Chief Commercial Officer, bringing more than 20 years of experience in the medical device and pharmaceuticals industries. Before joining KORU, he most recently served as Vice President and General Manager, Advanced Drug Delivery Systems at Becton Dickinson where he led growth initiatives across the injectable drug delivery platform. Prior to Becton Dickinson, he served as CEO of ZebraSci, a specialized provider of drug device combination product development services, where he led an effective turnaround and growth strategy that resulted in the company?s successful acquisition.
